免疫原性
药品
医学
药理学
计算生物学
免疫学
免疫系统
生物
作者
Anette Christine Karle
标识
DOI:10.3389/fimmu.2020.00698
摘要
Immunogenicity against biotherapeutic proteins (BPs) and the potential outcome for the patient are difficult to predict. In vitro assays that can help to assess the immunogenic potential of BPs are not yet used routinely during drug development. MAPPs (MHC associated peptide proteomics) is one of the assays best characterized regarding its value for immunogenicity potential assessment. This review is focusing on recent studies that have employed human HLA class II-MAPPs assays to rank biotherapeutic candidates, investigate clinical immunogenicity and understand mechanistic root causes of immunogenicity. Advantages and challenges of the technology are discussed as well as the different areas of application.
科研通智能强力驱动
Strongly Powered by AbleSci AI